热门资讯> 正文

BrainStorm Cell Therapeutics 2024年第四季度盈利预览

2025-03-29 00:45

Brainstorm细胞治疗(BCLI) 0

BrainStorm Cell Therapeutics (NASDAQ:BCLI) is scheduled to announce Q4 earnings results on Monday, March 31st, before market open.
The consensus EPS Estimate is -$0.27 (+32.5% Y/Y).
Over the last 1 year, BCLI has beaten EPS estimates 25% of the time and has beaten revenue estimates 0% of the time.

More on BrainStorm Cell Therapeutics

Seeking Alpha’s Quant Rating on BrainStorm Cell Therapeutics
Historical earnings data for BrainStorm Cell Therapeutics
Financial information for BrainStorm Cell Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。